{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gerber DE"],"funding":["National Cancer Institute Midcareer Investigator Award in Patient-Oriented Research","National Cancer Institute","NCI NIH HHS"],"pagination":["44-49"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5836800"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["117"],"pubmed_abstract":["BACKGROUND:KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analysis of KRAS mutant cancers in an earlier phase 2 study of erlotinib plus the oral MET inhibitor tivantinib, combination therapy was associated with substantial clinical benefit compared to erlotinib alone (progression-free survival [PFS] HR 0.18; P < 0.01). The current study was conducted to evaluate this combination further in KRAS mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS:Previously treated patients with advanced KRAS mutant NSCLC were randomized to receive either oral tiv"],"journal":["Lung cancer (Amsterdam, Netherlands)"],"pubmed_title":["Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer."],"pmcid":["PMC5836800"],"funding_grant_id":["K24 CA201543","K24CA201543-01","1R2C2CA148394-010"],"pubmed_authors":["Socinski MA","Huang C","Johnson ML","Neal JW","Hesketh PJ","Brahmer JR","Schiller JH","Chai F","Bastos BR","Subramaniam DS","Rosovsky RP","Wakelee HA","Kazakin J","Gerber DE","Lilenbaum RC","Schwartz B","Sequist LV","Dietrich MF","Shirai K","Kelly RJ","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.","description":"BACKGROUND:KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analysis of KRAS mutant cancers in an earlier phase 2 study of erlotinib plus the oral MET inhibitor tivantinib, combination therapy was associated with substantial clinical benefit compared to erlotinib alone (progression-free survival [PFS] HR 0.18; P < 0.01). The current study was conducted to evaluate this combination further in KRAS mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS:Previously treated patients with advanced KRAS mutant NSCLC were randomized to receive either oral tiv","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Mar","modification":"2025-06-01T03:55:15.546Z","creation":"2019-06-06T19:04:04Z"},"accession":"S-EPMC5836800","cross_references":{"pubmed":["29496255"],"doi":["10.1016/j.lungcan.2018.01.010"]}}